An observational study in Colitis, Ulcerative, Crohn Disease and Inflammatory Bowel Diseases, sponsored by Janssen-Cilag Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 16 of the 20 other live ones, and was the 43rd registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 18 · Phase 4 2
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 205 across the 28 interventional studies, 200 across the 15 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Ltd. is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
4 of the studies in Colitis, Ulcerative by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) receiving guselkumab in a real-world setting, and to evaluate treatment persistence (continuation) and clinical effectiveness (how well it works) in the overall population and in predefined participant subgroups. The study will also assess patient-reported outcomes, including fatigue (low energy), health-related quality of life (HRQoL), and treatment satisfaction. CD and UC are long-term diseases that cause inflammation in intestine (part of digestive system).
The study population will include participants with confirmed diagnosis of moderate-to-severe Crohn's disease (CD) or Ulcerative colitis (UC) disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with confirmed diagnosis of moderate-to-severe UC or CD treated with guselkumab as per standard clinical practice, according to the summary of product characteristics (SmPC) and local guidelines will be enrolled. Only data available from clinical routine will be collected in this study.
Persistence of Treatment with Guselkumab
Persistence of treatment with guselkumab will be defined as the time elapsed from the date of the first administration of guselkumab to its discontinuation date. The discontinuation date will be defined as the date that the next administration of guselkumab should have taken place for a paticipant after the last dose of treatment was administered.
Time frame: Up to Week 96
Percentage of Participants with Early Responses to Guselkumab Measured Using Patient Reported Outcome (PRO-2) for Crohn's Disease (CD)
Percentage of participants with early responses to guselkumab will be assessed using PRO-2, including stool frequency and abdominal pain in CD participants through the patient's electronic (e)-diary.
Time frame: Up to Week 12
Percentage of Participants with Early Responses to Guselkumab Measured Using PRO-2 for Ulcerative Colitis (UC)
Percentage of participants with early responses to guselkumab will be assessed using PRO-2, including stool frequency and rectal bleeding in UC participants through the patient's e-diary.
Time frame: Up to Week 12
Percentage of Participants with Early Responses to Guselkumab Measured Using Bowel Urgency (BU)
Percentage of participants with early responses to guselkumab using bowel urgency will be assessed and reported via patient e-diary. BU is defined as the sudden or immediate need to have a bowel movement, will be assessed using both a qualitative and a quantitative approach. For the qualitative assessment the presence as a binary yes/no outcome of the symptoms will be collected; for the quantitative assessment the severity of BU will be evaluated using the urgency numerical rating scale (UNRS) ranging from 0 to 10, where 0 = no urgency and 10 = worst possible urgency.
Time frame: Up to Week 12
Percentage of Participants Achieving Clinical Response for CD as Measured by Harvey-Bradshaw Index (HBI)
Percentage of participants reporting effectiveness with treatment guselkumab will be measured through the HBI for CD. The HBI consists of a 5-part questionnaire, assessing general wellbeing, AP, number of liquid stools per day, abdominal mass and complications. Clinical response for CD is defined as the HBI score less than or equal to (\<=) 4 or a decrease in HBI by greater than or equal to (\>=) 3 from baseline.
Time frame: Up to Week 96
Percentage of Participants Achieving Clinical Response for UC as Measured by Partial Mayo Score (PMS)
Percentage of participants reporting effectiveness with treatment guselkumab will be measured through the PMS for UC. The PMS comprises 3 categories: rectal bleeding, stool frequency, and physician assessment. Clinical response for UC is defined as the PMS score less than (\<) 4 or \>= 30 percent (%) reduction from baseline.
Time frame: Up to Week 96
Percentage of Participants Achieving Corticosteroid-free Clinical Remission and PRO-2 for UC
Corticosteroid-free clinical remission for UC is defined as no use of steroids for at least 30 days and PMS less than (\<) 2 and a rectal bleeding subscore of 0. Mayo scoring system is used to assess disease severity and treatment effectiveness.
Time frame: Up to Week 96
Percentage of Participants Achieving Corticosteroid-free Clinical Remission and PRO-2 for CD
Corticosteroid-free clinical remission for CD is defined as no use of steroids for at least 30 days and HBI score less than or equal to (\<=)4. HBI score is used to assess disease severity and treatment effectiveness.
Time frame: Up to Week 96
Characteristics of Participants Receiving Guselkumab Treatment: Age
Age of participants receiving guselkumab treatment will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Sex
Sex of participants receiving guselkumab treatment will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Weight
Weight of participants receiving guselkumab treatment will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Body Mass Index (BMI)
BMI of participants receiving guselkumab treatment will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Vital Signs [Systolic Blood Pressure {SBP} and Diastolic Blood Pressure {DBP}]
Vital signs (SBP and DBP) of participants will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Comorbidities
Number of participants with comorbidities will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Smoking Status and History
Number of participants with smoking status and history will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Inflammatory Bowel Disease (IBD) Related Data
Participants IBD related data at diagnosis will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Age at Diagnosis of UC/CD
Participants age at diagnosis will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Previous Diagnosis of Plaque Psoriasis, Arthritic Psoriasis, Previous Use of IBD Treatment
Participants with a previous diagnosis of plaque psoriasis, arthritic psoriasis and previous use of IBD treatment will be reported.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Disease Severity
Participants reporting the disease severity will be assessed.
Time frame: At Week 0
Characteristics of Participants with CD Receiving Guselkumab Treatment: Disease Location
Participants disease location will be assessed.
Time frame: At Week 0
Characteristics of Participants with UC Receiving Guselkumab Treatment: Disease Extent
Participants disease extent will be assessed.
Time frame: At Week 0
Characteristics of Participants Receiving Guselkumab Treatment: Presence of Extraintestinal Manifestations
Participants with presence of extraintestinal manifestations will be assessed.
Time frame: At Week 0
Percentage of Participants with Adverse Events (AEs) During Treatment with Guselkumab
An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can be any unfavorable and unintended sign (including an abnormal finding or lack of expected pharmacological action), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.
Time frame: Up to Week 96
Change in C-reactive protein (CRP) Levels
Change in CRP levels since guselkumab initiation will be reported. CRP is a marker of inflammation that will be measured by physicians following routine clinical practice.
Time frame: Baseline (Week 0) up to Week 96
Change in Faecal Calprotectin (Fcal) Levels
Change in Fcal levels since guselkumab initiation will be reported. The Fcal is a marker of inflammation that will be measured by physicians following routine clinical practice.
Time frame: Baseline (Week 0) up to Week 96
Percentage of Participants Receiving Concomitant IBD Medications
Percentage of participants receiving concomitant IBD medications for UC and CD will be reported.
Time frame: Up to Week 96
Change in Health-related Quality of Life (HRQoL) as Measured by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scale Score
SIBDQ is a 10-item instrument developed to assess the participants perception of their health status specifically related to IBD over the past two weeks. The SIBDQ evaluates the following dimensions: psychological well-being (feelings of emotional health and stability), physical well-being (the impact of disease symptoms on physical health), social function (the influence of the disease on social activities and interactions) and digestive function (the effect of gastrointestinal symptoms on daily life). The total score ranges from 10 (worst health) to 70 (best health).
Time frame: Baseline (Week 0) up to Week 96
Change in Fatigue Measured by Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) Scale Score
FACIT-F scale is a 13-item instrument that evaluates fatigue/tiredness and its impact on daily activities and functioning in chronic diseases. It includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (for example, sleeping and social activities) over the last 7 days. The total FACIT-F score ranges from 0 to 52, with a higher score indicating less fatigue.
Time frame: Baseline (Week 0) up to Week 96
Percentage of Participants Achieving Endoscopic Response in Participants with CD as Measured by Simple Endoscopy Score-CD (SES-CD)
Endoscopic response in participants with CD is defined as 50% improvement from baseline in SES-CD total score, or SES-CD total score \<4.
Time frame: Up to Week 96
Percentage of Participants Achieving Endoscopic Remission in Participants with CD as Measured by SES-CD
Endoscopic remission in participants with CD is defined as SES-CD total score \<=4 with at least 2 points reduction from baseline (Week 0) and no sub-score \>1 in any individual component total score (terminal ileum, right colon, transverse colon, left colon, rectum).
Time frame: Up to Week 96
Percentage of Participants Achieving Endoscopic Improvement in Participants with UC as Measured by Mayo Score
Endoscopic improvement in participants with UC is defined as a Mayo endoscopic score (MES) \<=1.
Time frame: Up to Week 96
Percentage of Participants Achieving Endoscopic Normalization in Participants with UC as Measured by Mayo Score
Endoscopic normalization in participants with UC is defined as a Mayo score =0.
Time frame: Up to Week 96
Percentage of Participants Achieving Histologic Improvement
Histologic improvement is defined as neutrophil infiltration in \<5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system, that is, Geboes score \<=3.1.
Time frame: Up to Week 96
Percentage of Participants Achieving Histologic Remission
Histologic remission is defined as the absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system, that is, Geboes score \<=2B.0.
Time frame: Up to Week 96
Percentage of Participants with CD Achieving Intestinal Ultrasound (IUS) Response
IUS (transmural) response in CD participants is defined as reduction of bowel wall thickness (BWT) of \>=25% or normalization \[\<=3 millimeter {mm}\] of the most affected segment.
Time frame: Up to Week 96
Percentage of Participants with CD Achieving IUS Remission
IUS (transmural) remission in CD participants is defined as normalization of BWT (\<=3 mm) and vascularity (no signal or short signal in color doppler of the most affected segment), in participants with increased BWT (\>3 mm) or alternatively a Bowel Ultrasound Score (BUSS) \<=3.52.
Time frame: Up to Week 96
Percentage of Participants with UC Achieving IUS Response
IUS response is defined as a decrease in Milan Ultrasound Criteria (MUC) \>=2 points. The MUC is a validated ultrasound-based scoring system used to assess disease activity in UC. It combines BWT and vascularization (using Doppler imaging) to predict disease course.
Time frame: Up to Week 96
Percentage of Participants with UC Achieving IUS Remission
IUS Remission is defined as normalization of BWT and of all other IUS parameters or as a MUC \< 4.3. The MUC is a validated ultrasound-based scoring system used to assess disease activity in UC. It combines BWT and vascularization (using Doppler imaging) to predict disease course. MUC score \< 4.3 is considered a significant indicator of endoscopic remission MES= 0.
Time frame: Up to Week 96
Change from Baseline in Satisfaction with Guselkumab Treatment Using Treatment Satisfaction Questionnaire for Medication (TSQM)
TSQM-9 is an abbreviated version of the 14-item TSQM, and is a reliable and valid measure to assess treatment satisfaction. It consists of 9 items distributed in the domains: side effects, effectiveness, convenience, and global satisfaction, with scores at each domain ranging from 0 to 100. with higher score indicating higher treatment satisfaction.
Time frame: Baseline (Week 0) up to Week 96
Percentage of Participants Receiving Guselkumab Treatment: Previous IBD-Related Surgeries
Percentage of participants receiving previous IBD-related surgeries will be reported.
Time frame: Up to 12 months
Change in Number of UC/CD Emergency Room Visits
Change in the number of emergency room visits for treatment of UC/CD will be reported.
Time frame: Up to Week 96
Change in Number of UC/CD-Hospitalizations
Change in the number of hospitalizations for treatment of UC/CD will be reported.
Time frame: Up to Week 96
Change in Number of UC/CD Surgeries
Change in the number of surgeries for treatment of UC/CD will be reported.
Time frame: Up to Week 96
Change from Baseline in Disability Assessed Through the Modified (m)IBD-Disk Score
mIBD-disk includes 10+1 items assessing abdominal pain, defecation, social life, professional life, sleep, energy, anxiety, self-image, sexual functions, joint pain and dietary habits. Participants rate each item on an 11-point visual analogue scale, ranging from 0 ("absolutely disagree") to 10 ("absolutely agree"). An average total IBD-Disk score of 40 (44 for the mIBD version) or higher is generally associated with a moderate-to-severe level of disability in individuals with IBD.
Time frame: Baseline (Week 0) up to Week 96
Change from Baseline in Presence and Evolution of Extra-Intestinal Manifestations (EIMs)
The assessment of the evolution of EIMs during guselkumab treatment will be performed by the physician on a 4-point Likert scale (1 = Recovered: the EIM has resolved completely; 2 = Improved: the EIM has shown clinical improvement but is not fully resolved. 3 = Unchanged: no change in the severity or status of the EIM; 4 = Worsened: the EIM has deteriorated or increased in severity from previous visit).
Time frame: Baseline up to Week 96
No study locations are listed for this record.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · innovativemedicine.jnj.com
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2029, 33 months later.
Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 33 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.